MedTrace Logo

Long-term Study Of Ropinirole In Restless Legs Syndrome

NCT00329602 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2017-03-23

Study results available
· View outcomes & findings →

Summary

This is an initial placebo-controlled study followed by open treatment evaluating the effectiveness and tolerability of ropinirole long-term in patients with moderate to severe Restless Legs Syndrome.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Placebo

Matching Placebo

DRUG

Ropinirole

Ropinirole IR 0.25mg/day to 4mg/day for RLS

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Australia
  • Czechia
  • Denmark
  • Germany
  • Italy
  • Norway
  • Portugal
  • Slovakia
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329602 on ClinicalTrials.gov